Molecular cancer therapeutics

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.

Molecular cancer therapeutics

Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D

New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.

Molecular cancer therapeutics

Barak Y, Thorne SH, Ackerley DF, Lynch SV, Contag CH, Matin A

New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.

Molecular cancer therapeutics

Barak Y, Thorne SH, Ackerley DF, Lynch SV, Contag CH, Matin A

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Molecular cancer therapeutics

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Molecular cancer therapeutics

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN

Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death.

Molecular cancer therapeutics

Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE

(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.

Molecular cancer therapeutics

Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE

Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides.

Molecular cancer therapeutics

Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE

Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.

Molecular cancer therapeutics

Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS

Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.

Molecular cancer therapeutics

Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS

Pages